Adicet Bio 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
one of the biotech analysts here at Guggenheim, and it's my pleasure to introduce our next company, Adicet Bio. And with us, we have the CEO, Chen Schor. Welcome, Ken, and it's a pleasure to have you here. Maybe, just to set the stage, why don't you tell us the story about the company for people who are not really familiar with that, and the latest updates, what shall we look for over the next 12, 18 months?
Sure. Absolutely. First of all, Delma, thank you for inviting us. Always glad to be here in the conference and look forward to a productive fireside chat. Adicet is a leading cell therapy company. We're focusing on a specific type of cells called gamma delta 1 T cells, and we also have an in vivo CAR T pipeline that we expect to update the market about in the very, very near future. On the cell therapy side, what's unique about gamma delta 1 T cells is that we can dose them completely off the shelf. These are allogeneic cells that can be dosed to patients. And gamma delta 1 T cells, unlike alpha beta T cells, tend to home to tissues.
A very low percent of our T cells in the blood are gamma delta 1 T cells, but rather a much higher percent in the tissues is gamma delta 1 T cells, which makes them ideal for autoimmune diseases and potentially also for solid tumors, because that's where the tissue presents itself. For example, in autoimmune diseases, we have these B cell islets that are associated with the disease. The other key advantage of gamma delta 1 T cells is they're generally very, very well tolerated, and have less events like CRS and ICANS and other type of events that are very predominant with the alpha beta CAR Ts, as we've seen in different datasets. We recently announced a dataset that included quite a few patients at 12 months. Not all of them were 12 months.
We expect to have a data update in the very, very near term, in the next few months, with all the patients completing at least 12 months, and an update, following our meeting with the FDA regarding the design of the pivotal study. We also expect in the next few months to update the market about our in vivo CAR T pipeline, and we have another program in solid tumors, for prostate cancer, that we expect to start dosing in Q1, and we'll have data over the next year.
Thank you for that great overview. Maybe stepping back to the platform. As you were saying, it's a pretty differentiated platform compared to the classical alpha beta CAR T cells, in vivo CAR T, we have the T cell regulators as well. How shall we think about the implication of this difference?
Sure. What are the advantages in terms of efficacy and safety?
Yes, absolutely. That's a very broad question. Essentially, the question was, how do you compare, and let's focus on LN and SLE. I think that's probably going to make it more relevant. How do you compare prula-cel versus other alpha beta T cells, bispecifics, in vivo CAR Ts, there's lentiviral approaches.
T cell engagers. and there's mRNA.
T cell B specific, that's the and mRNA nanoparticles. Let's kind of go, I'll start with the bottom line. I believe the data suggests so far that for autoimmune diseases, the therapies that can provide immunosuppressant-free remissions are either T cell, whether it's alpha beta or gamma delta, or lentiviral approaches.
In between, it's less likely that we're going to see. Let's first focus on the in between. There's room for everybody. Let's not be confused about it. Let's, for a second, focus on the in between. If you look at T cell engagers or bispecifics in the field of LN and SLE, we haven't seen. These have been developed for quite a few years. I just came back from ACR. We haven't seen any dataset that suggests that bispecifics can cause an immune reset and provide immunosuppressant-free remissions. When you talk with ACR, in ACR with investigators that are experienced with bispecifics, I haven't found one that told me, "You're not going to need chronic dosing with bispecifics." Will it work?
Yes, but it will be another version of immunosuppressants, probably maybe a little bit better than immunosuppressant, than obinutuzumab, maybe, but I don't think there's data yet to suggest that it's better than obinutuzumab. So, bispecifics, more like chronic immunosuppressants, like antibodies. If you talk about mRNA approaches, again, no data to support the efficacy, but they're overall predicted, and what we've heard from people that have clinical experience, to perform in the bispecific range. With alpha beta T cells, and when you look with gamma delta T cells, what you see is immunosuppressant-free remissions. So when you look at our dataset, we've seen approximately 50%-54%, either at 12 months, complete remission response or DORIS that are immunosuppressant-free. Generally, all the patients stopped taking their immunosuppressants. They went off their steroids, except for one. And they don't take any drugs. They feel much, much better.
That's consistent with the alpha-beta, what you see. The key advantage that we have is that we're off the shelf, and we're much better tolerated, and we understand why we're much better tolerated compared to the alpha-beta T cells. The lentiviral approach, I think, will eventually produce the same type of datasets, just like the alpha-beta T cells, but it's gene therapy.
I am not sure if you are an autoimmune patient, if gene therapy is the first choice you are going to go after if you can take a cell therapy approach.
Got it. That is really helpful. Maybe zooming in on the data that you have recently shown. So we have seen 12 months data. Can you help us contextualize the denominator? We received a lot of questions on that.
Sure. Compared to all the patients that you have enrolled, how many did you follow up, and can you contextualize the number that we saw?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
1 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
